Prognostic Implications of Codon-Specific KRAS Mutations in Localized and Advanced Stages of Pancreatic Cancer IDH-mutant brainstem gliomas have a characteristic clinical and radiographic phenotype.

Vorasidenib is the first oral targeted therapy authorised for the treatment of adults and paediatric patients aged 12 years and older with Grade 2 IDH-mutant gliomas, who have undergone surgical ...

A drug used to target IDH1 mutations in select cancers also appears to inhibit the wild-type form of the enzyme, under certain conditions. This feature explains why a large group of different cancers ...

The FDA approved vorasidenib (Voranigo) for patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation. The drug -- an IDH1 and IDH2 inhibitor - ...

The US Food and Drug Administration (FDA) has approved vorasidenib (Voranigo, Servier) for the treatment of certain isocitrate dehydrogenase (IDH)–mutant diffuse gliomas, marking the first approval of ...

Leonora Balaj, PhD, an investigator in the department of Neurosurgery at Massachusetts General Hospital and an assistant professor of Neurosurgery at Harvard Medical School, is co-senior author of a ...